An All Star Team


Michael Seiden, M.D. Ph.D.
Co-Founder and CEO

Dr. Seiden is a senior oncologist and business executive with extensive experience in drug development and healthcare management.

He has served as the CEO of the Fox Chase Cancer Center (2007-2013) as well as the Chief Medical Officer and President of US Onco

logy (2013-2021) a McKesson Company. In his last position, Dr. Seiden had oversight of US Oncology Research and 450 cancer delivery sites caring for over 1 million cancer patients across 23 states.


Dario Altieri M.D.
Co-Founder & Inventor

Dr. Altieri is an international expert in cancer biology with a 30-year history of funded research in the basic mechanisms of cancer growth and survival.

His previous roles included serving as a Professor at Yale in Pathology and the Founding Chair and Chair of Cancer Biology at the University of Massachusetts. Since 2010, he has served as the Cancer Center Director of the Ellen and Ronald Caplan NCI-designated cancer Center at Wistar. In 2015 he also assumed the role of President and Chief Executive Officer of The Wistar Institute.


Umar Hayat Ph.D.
Chief Technology Officer

Dr. Hayat is a serial entrepreneur with proven experience in chemistry, manufacturing and controls – from discovery through commercialization.
He is an expert in phase appropriate development and regulatory strategies – successful NDAs for Intermezzo®, Kerydin®, Eucrisa®, Veltasa® and now Orismilast (on its way).

His successful start up adventures includes Transcept (reverse merger with Paratek), Anacor acquired by Pfizer (5.2 BUS$) and Relypsa acquired by Vifor (1.52BUS$) .


Tim Coleman PhD MBA 
Chief of Staff

Dr. Coleman is a founder of private companies, scientist, inventor and enjoyer of all things zero to one! 

He is a designer, developer of precision medicines and targeting probes and a PI funded by NCI. He has extensive experience in oncology, immune, autoimmune and diseases of the brain.

His breadth includes finance and budgeting, licensing, investor outreach, funding proposal development, clinical trial design, drug biomarker development, and project planning.


Nicole Stephenson MS MBA 
Operations Manager

Nicole has worked in both pharma and academia, assisting and advising companies on strategic planning and Good Clinical Practices and pharmacovigilance compliance. She has successfully managed relationships with external partners as well as investigator-initiated studies. 

She has over 10 years of Secretarial Board duties including planning and distributing Board meeting materials and agendas, recording minutes, motion and vote tracking, reviewing governance documents and maintaining the official meeting minutes.


TM Ravi 
Board Member

T. M. Ravi is Managing Director and co-founder of The Hive – a venture studio and fund to co-create, fund and launch AI-powered enterprise startups. The Hive invests in early-stage startups and also engages with entrepreneurs and corporations to create companies focused on data and AI driven applications in the enterprise and vertical industry segments such as financial services, industrials, and life sciences & healthcare.

The Hive in the US was started in 2012 and is currently in its fourth fund.


Grant Bogle  
Board Member

Grant is a senior pharmaceutical and biotech executive. He was previously the CEO and Board Member of Epizyme, and the Chief Commercial Officer of Tesaro.

He has extensive transactional experience. Completed sale of Epizyme to Ipsen in 2022.

Grant is also a leader of Pharma Facing Sales and Strategic Alignment while Senior VP of Pharmaceutical and Biotech Solutions within McKesson Specialty Health.

And he has broad expertise in oncology as an operational leaders at US Oncology.

Gladius Therapeutics is bringing together world class talent with deep medical and operational experience.

This combination of people gives us the best shot we can get at fighting cancer.



© 2023 Gladius Therapeutics, Inc.

Sign up to receive news about
Gladius Therapeutics.